Key Highlights

● Three IPOs raised about $613 million at their offer prices.

● Two of the three deals priced at the bottom of their ranges.

● Of 135 US IPOs in 2026, 80 trade below their offer price.

● Health care stocks rose 2.4% Thursday to a record high.

Three new companies are set to start trading Friday, and they're debuting into one of the roughest tech mornings of the year. Bambusa Therapeutics (NASDAQ:BBTX), Aspen Neuroscience (NASDAQ:ASPE) and OPay (NYSE:OPAY) all priced their IPOs on Thursday night. Together they raised about $613 million at their offer prices, according to market data.

The three deals

Bambusa Therapeutics priced an upsized offering of 10.6 million shares at $16, the middle of its $15 to $17 range, raising about $168.8 million, according to market data and media reports. One IPO research firm describes it as an immunology and inflammation biotech, and it develops bispecific antibodies. BofA Securities, Evercore ISI, UBS and Cantor led the deal.

Aspen Neuroscience sold 9.375 million shares at $15, the low end of its $15 to $17 range, raising about $140.6 million. The San Diego company is developing a stem-cell therapy for Parkinson's disease. Leerink Partners, Piper Sandler, Stifel, UBS and Oppenheimer led the offering.

OPay priced 16 million shares at $19, the low end of its $19 to $21 range, for about $304 million. The research firm describes it as an emerging-markets fintech; it had set terms for a $320 million raise. Citigroup, Deutsche Bank, Standard Bank and CICC led the deal.

Tough timing, with one tailwind

The broader market isn't offering much help. Nasdaq-100 futures were down about 2.6% around 8 a.m. ET after Amazon (NASDAQ:AMZN) and Intel (NASDAQ:INTC) results reignited fears about AI cash burn, and S&P 500 futures were down about 1.1%. Two of the three deals priced at the bottom of their ranges, a sign that investors pushed back on valuation.

Biotech isn't a one-way bet, though. On Thursday, Alnylam (NASDAQ:ALNY) fell 25.1% and Iovance (NASDAQ:IOVA) 35.5%, according to a session recap, a reminder of how sharply individual drug developers can move on clinical or commercial news. Both of today's biotech debuts are clinical-stage stories, so early trading may be volatile. Bambusa and Aspen will join the Nasdaq Composite, which includes almost all common stocks listed on Nasdaq.

The two biotechs do have a sector tailwind. Health care stocks rose 2.4% on Thursday to a record high, and drugmakers including Regeneron (NASDAQ:REGN) and Gilead (NASDAQ:GILD) were up between 5% and 7% in pre-market trading. Bambusa's upsizing suggests Demand for immunology Assets is healthy even in a risk-off tape.

OPay faces a different backdrop. Fintech and crypto-linked stocks are under pressure after a $6.3 billion hack at crypto exchange Binance, with Coinbase (NASDAQ:COIN) and Robinhood (NASDAQ:HOOD) each down about 5% to 6% pre-market. OPay isn't directly connected to that event, but it shapes the mood for payment stocks.

What the IPO market is telling us

Returns on new issues have been weak this year. Of 135 US IPOs priced in 2026, 53 were trading above their Offer Price and 80 below as of Oct. 29, for a total return of -0.73% from issue, according to market data. Among the last 100 IPOs, the average gain from issue was 2.09%. Earlier this week, only SPACs had priced, and Georgia Banking Co. (NASDAQ:GBFH) completed a Nasdaq direct listing on Thursday.

Today's debuts also come as Anthropic prepares what the research firm estimates is a $75 billion IPO targeted for mid-November. How these three trade could signal how much appetite there is for new risk heading into that deal.

What to watch: opening prices versus offer levels, especially for the two deals that priced at the low end. A weak start would add to evidence that IPO buyers are demanding discounts.